

Global Insomnia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

https://marketpublishers.com/r/G671D37CF8DEN.html

Date: August 2019

Pages: 101

Price: US\$ 1,799.00 (Single User License)

ID: G671D37CF8DEN

Abstracts

High levels of pipeline activity are being observed in Insomnia treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Alexza Pharmaceuticals Inc, Amherst Pharmaceuticals LLC, Blake Insomnia Therapeutics Inc, Cennerv Pharmaceuticals Ltd, Cosmas Therapeutics Development Inc and others.

A Significant contribution to the Insomnia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Insomnia pipeline included 26 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Insomnia condition and increased access to investments is encouraging growth of Insomnia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Insomnia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Insomnia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2,



phase 3 and pre-registration phases are also analyzed.

The current report examines the current Insomnia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Insomnia. Further, orphan drug status, fast track designation, grants awarded and other special status for Insomnia pipeline compounds are also included. This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Insomnia pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Insomnia Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Insomnia drugs

Late phase: Phase 3 and in-approval Insomnia drugs

Companies involved in the Pipeline-

Company overview

Snapshot

Insomnia therapeutic treatment activities



Details for each Insomnia drug candidate-	
Snapshot	
Drug Name	
Alternative Names	
Company	
Originator	
Phase	
Molecule Type	
Orphan Drug Status	
Drug Overview	
Mechanism of Action	
Current Status	
Trial Details	
Other details	

Recent Insomnia therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

Pre-clinical trials for each drug candidate

Clinical trials for each drug candidate



Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Insomnia- Disease Overview
- 2.2 Insomnia- Pipeline Snapshot
- 2.3 Insomnia- Pipeline Drugs by Phase
- 2.4 Insomnia- Pipeline Drugs by Company
- 2.5 Insomnia- Pipeline Drugs by Mechanism of Action

3 COMPANY WISE PIPELINE ANALYSIS

- 3.1 Alexza Pharmaceuticals Inc Insomnia Drug Pipeline, H2-2019
- 3.2 Amherst Pharmaceuticals LLC Insomnia Drug Pipeline, H2- 2019
- 3.3 Blake Insomnia Therapeutics Inc Insomnia Drug Pipeline, H2- 2019
- 3.4 Cennery Pharmaceuticals Ltd Insomnia Drug Pipeline, H2- 2019
- 3.5 Cosmas Therapeutics Development Inc Insomnia Drug Pipeline, H2- 2019
- 3.6 Druggability Technologies Holdings Ltd Insomnia Drug Pipeline, H2- 2019
- 3.7 Eisai Co Ltd Insomnia Drug Pipeline, H2- 2019
- 3.8 Evotec AG Insomnia Drug Pipeline, H2- 2019
- 3.9 Grupo Ferrer Internacional SA Insomnia Drug Pipeline, H2-2019
- 3.10 Idorsia Pharmaceutical Ltd Insomnia Drug Pipeline, H2- 2019
- 3.11 Imbrium Therapeutics LP Insomnia Drug Pipeline, H2-2019
- 3.12 Intra-Cellular Therapies Inc Insomnia Drug Pipeline, H2- 2019
- 3.13 Janssen Pharmaceuticals Insomnia Drug Pipeline, H2- 2019
- 3.14 Leading BioSciences Inc Insomnia Drug Pipeline, H2- 2019
- 3.15 Linnet BioPharmaceuticals Inc Insomnia Drug Pipeline, H2- 2019
- 3.16 Merck & Co Inc Insomnia Drug Pipeline, H2- 2019
- 3.17 NB Health Laboratory Co Ltd Insomnia Drug Pipeline, H2- 2019
- 3.18 Neurim Pharmaceuticals Ltd Insomnia Drug Pipeline, H2- 2019
- 3.19 NeuroFix Therapeutics LLC Insomnia Drug Pipeline, H2- 2019
- 3.20 Overseas Pharmaceuticals Ltd Insomnia Drug Pipeline, H2- 2019
- 3.21 Reviva Pharmaceuticals Inc Insomnia Drug Pipeline, H2- 2019
- 3.22 Sage Therapeutics Inc Insomnia Drug Pipeline, H2- 2019



- 3.23 Shionogi & Co Ltd Insomnia Drug Pipeline, H2- 2019
- 3.24 Sosei Heptares Insomnia Drug Pipeline, H2- 2019
- 3.25 Taisho Pharmaceutical Holdings Co Ltd Insomnia Drug Pipeline, H2- 2019
- 3.26 Zelda Therapeutics Pty Ltd Insomnia Drug Pipeline, H2- 2019

4 PHASE 1 PIPELINE DRUG DETAILS

- 4.1 Insomnia- Phase 1 Drug Details
- 4.2 Insomnia- Phase 1 Drug Overview
- 4.3 Insomnia- Phase 1 Mechanism of Action
- 4.4 Current Status
- 4.5 Trial Details

5 PHASE 2 PIPELINE DRUG DETAILS

- 5.1 Insomnia- Phase 2 Drug Details
- 5.2 Insomnia- Phase 2 Drug Overview
- 5.3 Insomnia- Phase 2 Mechanism of Action
- 5.4 Current Status
- 5.5 Trial Details

6 PHASE 3 PIPELINE DRUG DETAILS

- 6.1 Insomnia- Phase 3 Drug Details
- 6.2 Insomnia- Phase 3 Drug Overview
- 6.3 Insomnia- Phase 3 Drug Mechanism of Action
- 6.4 Current Status
- 6.5 Trial Details

7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS

- 7.1 Insomnia- Pre-clinical Phase Drug Details
- 7.2 Insomnia- Pre-clinical Phase Drug Overview
- 7.3 Insomnia- Pre-clinical Phase Drug Mechanism of Action
- 7.4 Current Status
- 7.5 Trial Details

8 RECENT NEWS AND DEVELOPMENTS



9 APPENDIX

- 9.1 About VPAResearch
- 9.2 Sources and Research Methodology



I would like to order

Product name: Global Insomnia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval

Therapeutics, Companies and Markets

Product link: https://marketpublishers.com/r/G671D37CF8DEN.html

Price: US\$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G671D37CF8DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$



